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Abstract
The blood-brain barrier (BBB) efficiently restricts penetration of therapeutic agents to the brain from
the periphery. Therefore, discovery of new modalities allowing for effective delivery of drugs and
biomacromolecules to the central nervous system (CNS) is of great need and importance for treatment
of neurodegenerative disorders. This manuscript focuses on three relatively new strategies. The first
strategy involves inhibition of the drug efflux transporters expressed in BBB by Pluronic® block
copolymers, which allows for the increased transport of the substrates of these transporters to the
brain. The second strategy involves the design of nanoparticles conjugated with specific ligands that
can target receptors in the brain microvasculature and carry the drugs to the brain through the receptor
mediated transcytosis. The third strategy involves artificial hydrophobization of peptides and proteins
that facilitates the delivery of these peptides and proteins across BBB. This review discusses the
current state, advantages and limitations of each of the three technologies and outlines their future
prospects.
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1. Introduction
Tremendous attention, efforts, and hope are focused on the development of novel drug delivery
systems. The principal reason for the extremely rapid growth of research and technology in
this field is the realization that substantial improvement of current therapies will necessitate
the use of therapeutic modalities allowing for efficient and site-specific transport of drugs to
the target tissues affected by the disease. This necessity arises primarily due to the enormous
barriers that a drug molecule must overcome before it reaches its target site within the body.
One of the most challenging barriers in the body is the blood–brain barrier (BBB) that
significantly restricts the entry of compounds to the brain from the periphery. This impedes
the use of many low molecular weight drugs as well as biomacromolecules, such DNA and
proteins, for treatment of neurological diseases, especially at early stages of the disease when
the BBB remains intact. The low permeability of the BBB is attributed, in large part, to the
brain microvessel endothelial cells (BMVEC), which form tight extracellular junctions and
have low pinocytic activity (1,2). Passive diffusion of substances across the BMVEC may
occur depending on the lipophilicity and molecular weight of these substances. However, a
large number of compounds is rapidly effluxed from the brain into the blood by extremely
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effective efflux pumps expressed in the BBB (3–5). These efflux systems include P-
glycoprotein (Pgp) and Multidrug Resistance Proteins (MRPs). There is also an enzymatic
barrier to drug transport in BMVECs. Specifically, activity of many enzymes that participate
in the metabolism and inactivation of endogenous compounds, such as γ-glutamyl
transpeptidase, alkaline phosphatase, and aromatic acid decarboxylase is elevated in cerebral
microvessels (6,7). Aside from approaches that cause short-term disruption of the BBB, drug
delivery systems need to improve the transcellular routes of drug transport through the
BMVEC. Therefore, discovery of new modalities allowing for effective drug delivery to the
central nervous system (CNS) is of great need and importance for treatment of
neurodegenerative disorders. A number of earlier publications and extensive reviews on drug
and biomacromolecule delivery to the brain are available in the literature (8–18). The present
mini-review describes three relatively new approaches for improving drug transport through
the BBB: i) inhibition of drug efflux transporters in BBB by amphiphilic block copolymers
(Pluronic®), ii) using receptor-mediated transport of drugs encapsulated into nanoparticles,
and iii) artificial hydrophobization of peptides and proteins by fatty acid residues.
2. Inhibition of drug efflux systems in BBB by Pluronic® block copolymers
One emerging strategy to enhance drug delivery to the CNS is the co-administration with a
drug of a pharmacological modulator that inhibits drug efflux transport systems in BMVEC.
One promising example of such pharmacological modulators is represented by a class of
Pluronic® block copolymers (also known under non-proprietary name “poloxamers”). These
block copolymers consist of hydrophilic ethylene oxide (EO) and hydrophobic propylene oxide
(PO) blocks arranged in a basic A-B-A tri-block structure: EOn/2-POm-EOn/2. The block
copolymers with various numbers of hydrophilic EO (n) and hydrophobic PO (m) units are
characterized by distinct hydrophilic-lipophilic balance (HLB). Due to their amphiphilic
character these copolymers display surfactant properties including ability to interact with
hydrophobic surfaces and biological membranes. In aqueous solutions at concentrations above
critical micelle concentration (CMC) these copolymers self-assemble into micelles.
Studies in multidrug resistant (MDR) cancer cells, polarized intestinal epithelial cells, Caco-2,
and polarized BMVEC monolayers provided compelling evidence that selected Pluronic®
block copolymers can inhibit drug efflux transport systems (19–26). Specifically, in primary
cultured BMVEC monolayers, used as an in vitro model of BBB, the inhibition of Pgp efflux
system was associated with an increased accumulation and permeability of the Pgp probe,
rhodamine 123 (22). It was found that Pluronic® block copolymers also increase accumulation
and transport of the MRP probe, fluorescein, in these cells, thus suggesting possible inhibition
by the block copolymers of MRPs or MRP-like transporters present in the BBB (27).
Furthermore, these studies suggested that co-administration with the block copolymers
increases the permeability of a broad spectrum of drugs in the BBB.
The effects of Pluronic® block copolymers on Pgp and MRPs drug efflux transporters in the
BMVEC were most apparent at concentrations below the critical micellization concentration
CMC (21,22). Particularly, exposure of the BMVEC to low concentrations of P85 (ca. from
0.001%wt to 0.01%wt) resulted in increased rhodamine 123 accumulation, consistent with the
inhibition of the Pgp efflux transport protein. At higher concentrations of Pluronic® P85 (e.g.
1 % wt.) the inhibition of Pgp efflux system was diminished, and rhodamine 123 intracellular
levels were decreased. It was suggested that “unimers”, i.e. single block copolymer molecules,
are responsible for the inhibition of Pgp and MRPs efflux transport system (CMC for
Pluronic® P85 is 0.03%wt (28)). Incorporation of the probe into the micelles formed at high
concentrations of the block copolymer, decreases its availability to the cells and reduces the
transport of this probe in BMVEC (21,22).
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Recent findings suggest that effects of Pluronic® on drug efflux transport proteins involve
interactions of the block copolymers with the cell membranes (24,29). The hydrophobic PO
chains of Pluronic® immerse into the membrane hydrophobic areas, resulting in alterations of
the membrane structure, and decrease of its microviscosity (“membrane fluidization”) At
relatively low concentrations (e.g. 0.01 %), of Pluronic® inhibits the Pgp ATPase activity,
possibly, due to conformational changes in the transport protein induced by the immersed
copolymer chains in the Pgp-expressing membranes (24). In particular, Pluronic® P85
displayed the effects characteristic of a mixed type enzyme inhibitor - decreasing maximal
reaction rate, Vmax and increasing Michaelis constant, Km for ATP as well as Pgp-specific
substrates such as vinblastine (a detailed study is in preparation). The magnitude of these effects
for vinblasine was as high as over 200-fold Vmax/Km change (interestingly, MRP1 ATPase
activity was affected less, which could explain somewhat smaller effects of Pluronic® on this
transporter). In contrast, at the high concentrations (e.g. 1 %), binding of Pluronic® to the
membrane actually results in restoration of Pgp ATPase activity. This could be due to the
segregation of the block copolymer molecules in the 2D clusters in the membrane, which
diminishes its interactions with the transport proteins.
Various drug resistance mechanisms, including drug transport and detoxification systems,
require consumption of energy to sustain their function in the barrier cells. Because of this fact,
mechanistic studies have focused on the effects of Pluronic® block copolymers on metabolism
and energy conservation in BMVEC (24). The basis for such studies was the earlier reports
that Pluronic® block copolymers can affect mitochondria function and energy conservation in
the cells (30). A recent study have demonstrated that exposure to Pluronic® P85 induced
significant decrease in ATP levels in BMVEC monolayers (24). The observed energy depletion
was due to inhibition of the cellular metabolism rather than a loss of ATP in the environment.
The study by Rapoport et al. suggested that Pluronic® P85 can be transported into the cells and
decrease the activity of electron transport chains in the mitochondria (31). Remarkably the
ATP depletion induced by Pluronic® appears to be tightly linked to the specific cell genotype,
since this effect is observed selectively in the cells that overexpress Pgp (as well as MRPs)
(32,33). The explanation of this relationship still needs to be found, although it was speculated
that inhibition of ATP production in high energy-consuming cells, such as cells overexpressing
Pgp, results in the rapid exhaustion of intracellular ATP, i.e. ATP depletion (32). Overall, the
energy depletion (decreasing ATP pool available for drug transport proteins) and membrane
interactions (inhibiting of ATPase activity of drug transport proteins) are critical factors
collectively contributing to a potent inhibition of the drug efflux systems by Pluronic® (Figure
1) (24).
It was demonstrated that a fine balance between hydrophilic (EO) and lipophilic (PO)
components in the Pluronic® molecule should be accomplished to potent enable inhibition of
the drug efflux systems (29). Overall, the most efficacious block copolymers are those with
intermediate lengths of PO block and relatively hydrophobic structure (HLB < 20), such as
Pluronic® P85 or L61 (23). Hydrophilic block copolymers, which have an extended EO block,
do not incorporate into lipid bilayers and practically do not transport into the cells. As a result,
they have little effect on either Pgp ATPase activity or ATP levels, which explains their
negligible effect on Pgp efflux pump in BBMEC (29). Very lipophilic block copolymers with
long PO blocks anchor in the plasma membranes and remain there for an extended period of
time. As a result, although they are potent inhibitors of Pgp ATPase, they are not efficiently
transported into the cell, do not cause ATP depletion and have little net effect on Pgp efflux
system in BMVEC. In contrast, the block copolymers displaying intermediate lipophilicity
transport across the membrane, spread throughout the cytoplasm and reach mitochondria and
nuclei. They inhibit Pgp ATPase activity and decrease ATP intracellular levels, which
combined results in effective inhibition of drug efflux transport systems and enhanced drug
transport to the brain (24,29).
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Effect of Pluronic® P85 on drug transport into the brain was evaluated in animal experiments
(25). Brain delivery of a Pgp substrate, digoxin, administered intravenously in the wild-type
mice expressing functional Pgp, was greatly enhanced in the presence of Pluronic® P85. It was
found that the digoxin brain/plasma ratios in the Pluronic® treated animals were practically
the same as those in the knockout mice, an animal model that is deficient in both mdr1a and
mdr1b isoforms of Pgp. This suggests that co-administration of Pluronic® with the drug in
mice resulted in inhibition of Pgp in the BBB of the wild-type animals (25).
One possible concern in these studies is that that by virtue of inhibiting the ATP in BMVEC,
the copolymer may display toxic effects on the BBB. However, the ATP depletion was found
to be transient; following removal of the block copolymers from BMVEC monolayers the
initial ATP levels were restored (24). Although there were significant decreases in cellular
ATP following Pluronic® treatment, even during peak depletion of ATP by Pluronic® there
was no evidence of loss of barrier functions of BBB as demonstrated using 3H-mannitol as a
permeability marker both in vitro and in vivo (22,25). Moreover, Pluronic® does not affect the
glucose transporter, GLUT1, and only slightly inhibits lactate transporter, MCT1, the two
transporters playing an important role in the brain metabolism (in preparation). A histochemical
examination of the tissue sections obtained from animals treated with Pluronic® revealed no
pathological changes in the BBB. Importantly, no cerebral toxicity of any kind has been
observed in the human Phase I studies of SP1049C, a Pluronic®-based formulation of
doxorubicin to treat MDR tumors (34). After completion of phase I clinical trials, SP1049C is
undergoing several phase II clinical trials. It is possible, that this formulation, evaluated in
human trials, can be adopted for the use with CNS drugs to enhance drug delivery to the brain.
3. Receptor-mediated delivery of nanoparticles to the brain
While the transport of many small molecules to the brain is a difficult task, the transport of
biomacromolecules such as DNA or proteins across the BBB presents an even more formidable
challenge. Nevertheless, some naturally occurring peptides can effectively pass this barrier due
to receptor-mediated transport (transcytosis) (18,35–37). Furthermore, homing peptides
exhibiting specific targeting to the brain can be selected from phage display libraries (38).
Therefore, utilizing the specific peptides for targeting of macromolecules and their receptor-
mediated transcytosis across BBB could be a successful strategy for improving drug delivery
to the brain.
A number of studies proposed approaches to accomplish receptor-mediated transcytosis of
biomacromolecules across the BBB (37). For example, coupling of oligonucleotides (ODNs)
with OX26 monoclonal antibody to the rat transferrin receptor was used in an attempt to
enhance brain uptake of biotinylated ODNs (39,40) and neurotrophin peptides (41). While
these studies demonstrated the potential of receptor-mediated transcytosis across the BBB for
delivery of biomacromolecules to the brain, they also revealed some limitations of this
approach. In particular, the while ODN-OX26 constructs displayed efficient transport across
BMVEC in vitro, their intravenous administration in vivo was much less successful, because
of the binding of these constructs with the plasma proteins.
This reinforces the idea that to be useful in drug delivery across the BBB the brain-specific
peptides need to combined with an appropriate drug carrier. The need for a carrier is highlighted
by the fact that many biomacromolecules have low hydrolytic stability and are subject to
degradation by blood proteins or by enzymes encountered in the BBB, which can be overcome
by incorporating these biomacromolecules into protective carrier species. The concept of using
polymeric drug carriers in combination with the targeting moieties is, generally speaking, very
attractive (42). A single unit of a given polymeric drug carrier can incorporate many molecules
of drug or biomacromolecules, resulting in high “payloads” per one targeting moiety and/or
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receptor engaged. Furthermore, by increasing the payload of the carrier, one might improve
the efficacy of the delivery while maintaining a relatively low level of involvement of numbers
of targeted moieties and receptors.
To allow for efficient transcytosis across the BMVEC the carrier particles have to be small
with the size not exceeding ca. 100 nm. The use of nanoparticles as vehicles for drug and gene
delivery has been an area of intensive research and development for over a decade (43–46).
Some examples, include solid nanoparticles (44,47,48), liposomes (49–51) and polymer
micelles (52–56). The surface of such carriers is often modified by poly(ethylene glycol) (PEG)
1 brush (“PEGylation”) to increase the stability of nanoparticles in dispersion and extend
circulation time of nanoparticles in the body (46,57–59). The targeting moieties, such as
peptides, can be attached to the ends of the PEG chains at the external side of the brush to allow
for the binding of these moieties with their specific receptors.
One of the early studies of targeted drug delivery to the brain used Pluronic® block copolymers
micelles as carriers of solubilized drugs (60,61). These micelles were conjugated with either
antibodies to the brain-specific antigens or insulin as a moiety to target insulin receptors at the
lumenal side of BMEC. Both, the antibody-conjgated and insulin-conjugated micelles were
shown to effectively deliver a drug incorporated into the micelles to the brain tissue in vivo.
Subsequent studies demonstrated that the micelles conjugated with insulin undergo receptor-
mediated transport in BMVEC (22). Insulin receptor appears to be promising target for drug
delivery to the brain using the carrier technology. A recent study reported targeting of plasmid
DNA encapsulated into the PEGylated liposomes using monoclonal antibodies to the human
insulin receptor, human epidermal growth factor receptor (EGFR), or rat transferrin receptor
(62). The studies using human and rat glioma cells suggested 100- to 200-fold higher levels of
gene expression when the insulin receptor was targeted compared to the two other receptor
targets used. The same group has demonstrated that immunoliposomes carrying a therapeutic
antisense EGFR gene can be successfully delivered to EGFR-dependent brain gliomas in
vivo, resulting in gene expression and reduction of the tumor growth (63).
A new family of carrier systems, Nanogel™ was recently developed for targeted delivery of
drugs and biomacromolecules to the brain (64,65). Nanogel™ represents a nanoscale size
polymer network of cross-linked ionic polyethyleneimine (PEI) and nonionic poly(ethylene
glycol) (PEG) chains (PEG-cl-PEI). Figure 2 shows a schematic the Nanogel™ delivery system.
Nanogel™ forms swollen cross-linked networks dispersed in solution (panel a). Upon binding
of a macromolecular drug through electrostatic interaction of this drug with PEI chain
Nanogel™ collapses resulting in decreased volume and size of the particles (panel b). Because
of the effect of PEG chains, the collapsed Nanogel™ forms a stable dispersion with the particles
size of ca. 80 nm. Nanogel™ can absorb spontaneously, through ionic interactions, a broad set
of biomacromolecules, including negatively charged ODNs. One advantage is that
Nanogel™ displays efficient loading of macromolecules (40–60% by weight), resulting in high
“payloads” not achieved with conventional carrier systems.
Figure 2 panel c presents an electron microscopy of Nanogel™ loaded with the ODN. The
ODNs incorporated into the Nanogel™ were protected against degradation by nucleases.
However, upon delivery within a target cell the ODNs were released and exhibited specific
activity against their molecular targets, as demonstrated using several cell models (64). The
study using bovine BMVEC monolayers, as an in vitro model, demonstrated that following
incorporation in the Nanogel™ particles the transport of ODNs across BBB was significantly
increased compared to the free ODNs transport (64). Furthermore, the Nanogel™-incorporated
ODNs were protected from degradation in BMVEC. This study also tested Nanogel™ system
1Same as poly(ethylene oxide) or PEO
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for the receptor-mediated delivery of ODNs across BMVEC monolayers. Specifically, to target
the receptors displayed at BMVEC the surface of the Nanogel™ particles was modified by
either transferrin or insulin using avidin-biotin coupling chemistry. Both peptides were shown
to increase transcellular permeability of the Nanogel™ and enhance delivery of ODN across
BMVEC monolayers. Recent in vivo studies demonstrated that intravenously
administered 3H-ODN encapsulated in Nanogel™ was accumulated in the brain (in
preparation). These studies suggest that Nanogel™ is one promising carrier delivery of
biomacromolecules to the brain.
4. Artificial hydrophobization of peptides and proteins for delivery to CNS
Aside from the use of brain-specific peptides as targeting moieties there is a tremendous need
to enhance delivery of therapeutic peptides and proteins to the brain to treat neurodegenerative
disorders. Some examples, include Parkinson’s and Alzheimer’s diseases (66–68), lysosomal
diseases (69,70), and human obesity (18,71). BBB significantly restricts and controls the
exchange of peptides and regulatory proteins between the CNS and the blood. The only peptides
that cross the BBB to any appreciable extent utilize receptor-mediated endocytosis (e.g. insulin,
insulin-like growth factor, and transferrin) (72). The hydrophilicity, the lack of stability due to
enzymatic or chemical degradation, and the lack of transport carriers capable of shuttling
proteins across cell membranes, all play a part in precluding most peptides and proteins from
uptake into and transport into the brain (73). The attempts were made to covalently modify
peptides and proteins to enable their transport to the brain. For example, early studies reported
that modification of immunoglobulins with cationic groups (“cationization”) resulted in the
enhanced uptake of these proteins into the cells and delivery of these proteins to the brain
(74–76).
One useful strategy to enhance binding and uptake of proteins in the cells involves artificial
hydrophobization of these proteins with fatty acid residues (77–80). This technology involves
introduction of a very small number of residues of a fatty acid (e.g. stearic, palmitic, oleic) into
the protein molecules, specifically, 1 to 2 residues per protein globule. As a result of such
“gentle” modification the protein molecule remains water-soluble but it also acquires
hydrophobic anchor groups that can target even very hydrophilic proteins to the cell surfaces.
To obtain low and controlled degrees of modification of proteins with water-insoluble reagents
a modification procedure has been developed, which utilizes system of reverse micelles of a
surfactant, sodium bis-(2-ethylhexyl)sulfosucciate (Aerosol OT) in octane (77). After
solubilization in such colloidal system, which has very low content of water (less that 1 % wt.),
the protein molecule becomes entrapped into the inner water pool of the reverse micelle,
acquiring a monolayer cover of the hydrated surfactant molecules (Figure. 3). The size of the
water pool can be easily altered by changing the ratio [H2O]/[Aerosol OT]. The water-insoluble
reagent is localized not only in the bulk phase of the organic solvent but also incorporated into
the surfactant layer of the micelle coming into contact with the modified group of the protein.
Following the completion of the reaction the modified protein is precipitated and the surfactant
and excess of the reagent are removed by adding cold acetone. By conducting the reaction in
the microheterogeneous environment of the reverse micelles the protein conjugates with strictly
controlled and low degree of modification can be obtained. Over a dozen water-soluble proteins
(enzymes, antibodies, toxins, cytokines) were modified using this technique with their
functional activity being preserved after the modification (77,81–87).
Further, extensive studies of the fatty acylated proteins with artificial lipid membranes and
cells were conducted by us and others (77,82,84,87–91). Briefly, the results of these studies
are illustrated by the schematic presented in Figure 4. First, in all cases modification of water-
soluble proteins with fatty acid residues resulted in enhanced binding of these proteins with
lipid membranes due to the anchoring effect of the hydrophobic group. Second, in selected
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cases when the specific fatty acid binding receptors were present at the cell surface (e.g.
hepatocytes) the binding was enhanced to an even greater extent, presumably, due to the
targeting of this receptor by the fatty acid residue attached to the protein. Third, when the
protein had a receptor expressed at the cell surface, fatty acylation and specific interaction with
the receptor combined resulted in a cumulative effect promoting very strong binding of the
protein with the cell membrane. In addition to the enhanced binding to the cell surface there
was a significant increase in the uptake of the fatty acylated proteins into the cells (78). In
selected cased such modification resulted in translocation of the protein across the cell
membrane into the cytoplasm (e.g. increased toxicity of ricin A chain (82)). However, in most
cases the internalized fatty acylated protein remained entrapped in the endocytic vesicles within
the cell and was not released into the cytoplam (87). Nevertheless, when the protein displayed
biological effect in the cells, mediated by specific receptor(s), the activity of this protein, as a
result of fatty acylation was greatly increased. Specific examples include increase of
antiproliferative activity of Staphylococcus aureus enterotoxin A and recombinant α-inerferon
by ca. 100- and 1000- respectively (82,84). Finally, fatty acylated antibodies against virus-
specific antigens displayed the ability to inhibit virus reproduction in the cells, whereas
unmodified antibodies had practically no effect on the virus growth (81,92). This effect was
also explained by a combination interaction of the modified antibodies with the infected cells
involving specific binding with virus antigens (via the antibody active center), and non-specific
binding with membranes (via the fatty acid residues) (88). As a result, the modified antibodies
disrupted the essential stages of virus reproduction in the cells including the virus particle
assembly and budding.
The interest to this technology as related to CNS delivery of proteins was precipitated by the
finding that antibodies against brain specific-antigens and antibody Fab fragments, as a result
of fatty acylation, acquire the ability to accumulate in the brain after systemic administration
(83,93). Specifically, five days after administration the amounts of Fab fragments modified
with stearic acid residues appeared to be ca. 20 times higher in the brain than in other organs
(liver or kidney). Furthermore, a neuroleptic drug conjugated with the modified Fab fragments
appeared to be more efficiently delivered to the brain than the free drug. Interestingly, fatty
acylated Fab fragments of non-specific antibodies did not accumulate in the brain to the extent
observed with their brain-specific counterparts. These modified Fab fragments were
accumulated mainly in the liver. This suggests that combination of interactions involving both
the fatty acid residues and the antigen-binding site is essential for the delivery of the modified
antibodies in the brain tissue.
Subsequently, evidence began to mount that delivery of the fatty acylated proteins to the brain
might involve enhanced transcytosis of these proteins across BMVEC. In particular, a group
of French investigators, using Aerosol OT reversed micelles, synthesized a fatty acylated
ribonuclease A (Rnase A) and demonstrated that as a result of such modification the enzyme
acquired an ability to cross BMVEC monolayers with little, if any, degradation (90).
Specifically, the transport of acylated RNase A across bovine BMVEC monolayers was
increased 10-fold compared to the non-modified enzyme. Noteworthy, for successful
translocation of RNase A across the BMVEC monolayers a minimal length of the fatty acid
residue of 16 carbon atoms (stearoyl residue) was required.
The mechanism of the enhanced transport of fatty acylated proteins in the BBB at present
remains unknown. However, the technology involving fatty acylation of peptides and proteins
for their delivery to the brain could be very promising. The long-chain fatty acids are present
in the body in high amounts and could be much less harmful, compared to many ligands capable
of receptor-mediated binding and transport in the BBB, which can also display various side
effects. Fatty acid binding proteins (FABPs), which facilitate uptake, transport, and targeting
of long-chain fatty acids are expressed in many tissues, particularly, in neural tissue, including
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brain FABP (B-FABP), and myelin FABP (M-FABP) (94–97). Some involvement of FABP
in the transport and biodistribution of the fatty acylated proteins in the body is possible and it
needs to be evaluated in subsequent studies. Furthermore, it is noteworthy that fatty acid
modification of proteins can actually reduce immunogenicity of these proteins and decrease
production of antibodies against them (98). This result suggests a simple strategy for reducing
the immunogenicity of foreign proteins and for decreasing the risk of immunological
complications in therapy, which could be an additional benefit in the studies of the CNS
delivery of therapeutic peptides and proteins. One should expect the rapid increase of the
studies using artificially hydrophobized peptides and proteins in the near future.
5. Conclusions
Novel drug delivery systems promise new opportunities in the therapy of acute and chronic
brain disease. The transport of the drugs to the brain can be improved by inhibition of drug
efflux transport proteins, such as Pgp, which are important gatekeepers in the BBB. Alternative
strategies, involve the use of polymer nanocarriers, such as Nanogel™, which can be targeted
to the brain by attaching specific peptides to their surface. Finally, a new promising strategy
for the brain delivery of peptides and proteins is emerging, which involves artificial
hydrophobization of the protein (peptide) molecule with fatty acid residues. Overall, the design
of successful formulations for CNS delivery low molecular drugs and biomacromolecules will
require clear understanding and careful consideration of the mechanisms for the transport,
accumulation and elimination of these drugs in the brain.
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Schematic illustrating two-fold effects of Pluronic® block copolymers with intermediate
lipophilicity on Pgp and MRPs drug efflux system. These effects include (a) decrease in
membrane viscosity (“fluidization”) resulting in inhibition of Pgp and MRPs ATPase activity,
and (b) ATP depletion in BMVEC. Extremely lipophilic or hydrophilic Pluronic® block
copolymers do not cross the cellular membranes and do not cause energy depletion in the cells.
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Schematic illustration of Nanogel™ principle using a model: (a) swollen Nanogel™ has large
pores, through which the drug (“ball”) can enter; (b) binding of a drug to results in
Nanogel™ collapse. (c) Transmission electron microphotograph of PEG-cl-PEI Nanogel™
loaded with ODN. Bar = 50 nm. PEG-cl-PEI networks were synthesized by cross-linking of
PEI (M≈25000) with double end N,N′-carbonyldiimidazole-activated PEG (Mn≈8000) using
the emulsification-solvent evaporation technique (64). Following the synthesis the
Nanogel™ particles were fractionated by gel-permeation chromatography and a fraction with
an average particle diameter of ca. 250 nm was used for complex formation with
phosphorothioate ODN.
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Chemical modification of the protein with a water-insoluble reagent in the reverse micelles of
Aerosol OT in octane (77). The protein molecule is entrapped in the reverse micelle is
surrounded by a cover of hydrated surfactant molecules. The water-insoluble reagent is located
in the bulk organic phase and can be incorporated into the micelle surface layer coming in
contact with the reactive group in the protein. After completion of the reaction the reverse
micelle system is disintegrated and the protein is precipitated by cold acetone.
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Schematic representation of major mechanisms of interaction of fatty acylated proteins with
cell membranes: (a) attachment to the lipid membrane by the fatty acid anchor group; (b)
binding with fatty acid receptor; (c) two-point attachment via the the fatty acid anchor and
specific binding with the protein receptor.
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